Blueprint Medicines' Ayvakit (avapritinib), a treatment for gastrointestinal stromal tumors (GIST), was put on the list for priority review by China's Center for Drug. Evaluation (CDE). 29 July 2020
California, USA-based IACTA Pharmaceuticals and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical (ZKO), a leading Hong Kong-based pharmaceutical company, have entered into a definitive license agreement on the licensing of two of the company's products, IC 265 for dry eye and IC 270 for allergic conjunctivitis. 28 July 2020
Milan’s Enthera Pharmaceuticals has raised 28 million euros ($33 million) in a series A financing round. The firm is working on stem cell-based therapies for autoimmune conditions. 28 July 2020
Innovative biotech companies will be able to apply for access to a share of £30 million ($39 million) in grant funding through the UK’s relaunched Biomedical Catalyst. 27 July 2020
Novartis’ generics business, Sandoz, is to undertake a joint investment with the Austrian government to boost antibiotics manufacturing in Europe. 27 July 2020
Swedish Orphan Biovitrum, also known as Sobi, said that, following the negative opinion recommending a refusal to its marketing authorization application (MAA) by the European Medicines Agency’s Committee for Medicinal Products for Human use (CHMP) for its emapalumab, the company will apply for a re-examination. 27 July 2020
On the evening prior to the presentation of its second quarter results, US biotech Biogen announced that its chief financial officer Jeffrey Capello would be stepping down. 22 July 2020
CureVac AG, a clinical-stage German biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, has announced the closing of its latest private financing round, raising a total of $640 million (560 million euros). 22 July 2020
Partners Pfizer and BioNTech have announced initial data from their ongoing German Phase I/II, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. 20 July 2020
China-based clinical stage biopharma firm JW Therapeutics, which is focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong) Limited. 20 July 2020
Florida, USA-based private clinical-stage biopharma Cytocom today announced the acquisition of ImQuest Life Sciences, a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction. 20 July 2020
Principia Biopharma shot up due to swirling rumors regarding Sanofi's interest in the firm, Avisol Capital Partners noted on the Seeking Alpha blog last Friday. 20 July 2020
Clinical-stage Canadian biopharma company Liminal BioSciences today announced that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals, thus acquiring a pre-clinical research program of small molecule antagonists. 17 July 2020
UK-based Verona Pharma has raised approximately $200 million through a private placement of shares led by new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, and others. 17 July 2020
As Taiho Oncology, a US subsidiary of Japan’s Taiho Pharmaceutical, continues to add early- and late-stage assets to its expanding oncology portfolio, the company today announced the hiring of Dr Stephen Yoder, as vice president, business development, effective June 15, 2020. 15 July 2020
Following the launch of the AMR Action Fund, Brighton, UK-based Destiny Pharma has commented on the urgent need for such resources to combat the rise of antimicrobial resistance. 15 July 2020
Final results have been presented from the PUPs A-LONG and PUPs B-LONG studies assessing Elocta (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) in previously untreated patients (PUPs) with hemophilia A and B, respectively. 14 July 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024